FMP
Lexicon Pharmaceuticals, Inc.
LXRX
NASDAQ
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
0.756 USD
0.0171 (2.26%)
About
ceo
Dr. Michael Exton Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.lexpharma.comexchange
NASDAQ
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
CIK
0001062822
ISIN
US5288723027
CUSIP
528872302
Address
2445 Technology Forest Bouleva...
Phone
281 863 3000
Country
US
Employee
285
IPO Date
Apr 7, 2000
Key Executives
